161 related articles for article (PubMed ID: 36271373)
21. Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: A case report.
Zhou P; Zhang Q; Zhu J; Li P
Pathol Res Pract; 2021 Aug; 224():153489. PubMed ID: 34091389
[TBL] [Abstract][Full Text] [Related]
22. Integrated multi-omics profiling reveals a clinically relevant molecular feature and potential therapeutic target on phyllodes tumors of breast.
Xu W; Ma W; Wang D; Zhou X; Wang K; Mu K
Transl Oncol; 2024 May; 46():101998. PubMed ID: 38761630
[TBL] [Abstract][Full Text] [Related]
23. Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma.
Bot FJ; Sleddens HF; Dinjens WN
Diagn Mol Pathol; 1998 Dec; 7(6):295-301. PubMed ID: 10207667
[TBL] [Abstract][Full Text] [Related]
24. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
[TBL] [Abstract][Full Text] [Related]
25. Whole-genome profiling helps to classify phyllodes tumours of the breast.
Laé M; La Rosa P; Mandel J; Reyal F; Hupé P; Terrier P; Couturier J
J Clin Pathol; 2016 Dec; 69(12):1081-1087. PubMed ID: 27207013
[TBL] [Abstract][Full Text] [Related]
26. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours.
Jones AM; Mitter R; Poulsom R; Gillett C; Hanby AM; Tomlinson IP; Sawyer EJ;
J Pathol; 2008 Dec; 216(4):408-17. PubMed ID: 18937276
[TBL] [Abstract][Full Text] [Related]
27. Genomic landscapes of breast fibroepithelial tumors.
Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
[TBL] [Abstract][Full Text] [Related]
28. Genomic profiling by array comparative genomic hybridization reveals novel DNA copy number changes in breast phyllodes tumours.
Kuijper A; Snijders AM; Berns EM; Kuenen-Boumeester V; van der Wall E; Albertson DG; van Diest PJ
Cell Oncol; 2009; 31(1):31-9. PubMed ID: 19096148
[TBL] [Abstract][Full Text] [Related]
29. Phyllodes Tumor of the Breast in Pregnancy and Lactation.
Alipour S; Eskandari A
Adv Exp Med Biol; 2020; 1252():137-142. PubMed ID: 32816274
[TBL] [Abstract][Full Text] [Related]
30. Phyllodes Tumor of the Breast during Pregnancy and Lactation; A Systematic Review.
Alipour S; Eskandari A; Johar FM; Furuya S
Arch Iran Med; 2020 Jul; 23(7):488-497. PubMed ID: 32657600
[TBL] [Abstract][Full Text] [Related]
31. Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast.
Kim JY; Yu JH; Nam SJ; Kim SW; Lee SK; Park WY; Noh DY; Nam DH; Park YH; Han W; Lee JE
Transl Oncol; 2018 Feb; 11(1):18-23. PubMed ID: 29145046
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
[TBL] [Abstract][Full Text] [Related]
33. Borderline and malignant phyllodes tumors display similar promoter methylation profiles.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Virchows Arch; 2009 Dec; 455(6):469-75. PubMed ID: 19924440
[TBL] [Abstract][Full Text] [Related]
34. Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
Gensini F; Sestini R; De Luca A; Pinna V; Daniele P; Orzalesi L; Petrella MC; Porfirio B; Papi L
Fam Cancer; 2021 Jul; 20(3):195-199. PubMed ID: 33210232
[TBL] [Abstract][Full Text] [Related]
35. A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil.
Giacomazzi J; Koehler-Santos P; Palmero EI; Graudenz MS; Rivero LF; Lima E; Pütten AC; Hainaut P; Camey SA; Michelli RD; Neto CS; Fitarelli-Kiehl M; Geyer G; Meurer L; Geiger A; Azevedo MB; da Silva VD; Ashton-Prolla P
Virchows Arch; 2013 Jul; 463(1):17-22. PubMed ID: 23794094
[TBL] [Abstract][Full Text] [Related]
36. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast.
Vidal M; Peg V; Galván P; Tres A; Cortés J; Ramón y Cajal S; Rubio IT; Prat A
Mol Oncol; 2015 Jun; 9(6):1081-90. PubMed ID: 25687451
[TBL] [Abstract][Full Text] [Related]
37. CD34, CD117, and actin expression in phyllodes tumor of the breast.
Chen CM; Chen CJ; Chang CL; Shyu JS; Hsieh HF; Harn HJ
J Surg Res; 2000 Dec; 94(2):84-91. PubMed ID: 11104647
[TBL] [Abstract][Full Text] [Related]
38. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
39. FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
Wilkins A; Chauhan R; Rust A; Pearson A; Daley F; Manodoro F; Fenwick K; Bliss J; Yarnold J; Somaiah N
Breast Cancer Res Treat; 2018 Aug; 170(3):573-581. PubMed ID: 29700676
[TBL] [Abstract][Full Text] [Related]
40. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
